The fall sitting of the PEI College of Pharmacists jurisprudence exam will be held Monday, October 26, 2015 at 9:30 am at the College office. Deadline for registration is Friday, October 23, 2015 at 4:00pm. The application can be found under the licensing tab.
Drug Administration webinar
The PEI College of Pharmacists, in partnership with the PEI Pharmacists Association will be offering a webinar September 16, 2015 from 6:30-8:00 pm that will review drug administration in PEI. Please contact the PEI College of Pharmacists office at firstname.lastname@example.org if you are interested in attending. The program will be accredited for 1.5 CEUs.
PEBC Evaluating Exam The PEI College of Pharmacists is pleased to announce that the Pharmacy Examining Board of Canada will be offering a sitting of the PEBC Evaluating exam, in Charlottetown, Saturday October 17th, 2015. The deadline for registration is June 26, 2015. For more information on applying for the exam, visit the PEBC website www.pebc.ca.
National Pharmacy Technician Bridging Program now available online at Selkirk College. Visit www.napra.ca or www.selkirk.ca for more information.
Healthy Canadians -Recalls and Safety Alerts - MedEffect Canada - For Health Professionals
New information intended for health professionals about safety and therapeutic effectiveness of marketed health products.
Co-administration of repaglinide and clopidogrel (a CYP2C8 inhibitor) may lead to a significant decrease in blood glucose levels due to a drug-drug interaction.
The concomitant use of repaglinide and clopidogrel is now contraindicated.
The prescriber information for GLUCONORM (repaglinide) has been updated. The prescriber information for PLAVIX (clopidogrel) is currently being updated. The prescriber information for the generic products will be updated (see Products affected).
Teva Canada Limited in consultation with Health Canada has initiated a voluntary recall of one lot each of Cefoxitin (1g/vial; lot number 0001D4 and 10g/vial; lot number 0001D4) Injection due to the presence of dark Active Pharmaceutical Ingredient (API) particles in the vials, observed by visual inspection only upon reconstitution. The presence of particles in vials of the affected lot could pose the following risks, if injected: local inflammation, phlebitis, allergic response, infection and/or embolization in the body. The number of particles observed is very low, therefore the likelihood of a health hazard occurring in a patient who is administered this product is low.